We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Addex (ADXN) Terminates Parkinson's-Related Dyskinesia Study
Read MoreHide Full Article
Shares of Addex Therapeutics Ltd (ADXN - Free Report) tanked on Friday after the company announced that it has terminated the phase IIb/III study evaluating its pipeline candidate, dipraglurant, as a potential treatment for dyskinesia associated with Parkinson’s disease (PD-LID).
The company decided to stop the study owing to the slow recruitment of patients due to COVID-19-related patient concerns over participation in studies. The decision was also taken due to staffing shortages and patient turnover at study sites.
However, the company has stressed that the study termination was not due to dipraglurant.
Shares of Addex have plunged 46.8% so far this year compared with the industry’s decrease of 27.3%.
Image Source: Zacks Investment Research
As a result of the termination of the dipraglurant program for PD-LID, the company subsequently decided to suspend its financial guidance. Addex remains focused on advancing its preclinical candidates into clinical development and entering strategic collaborations for pipeline development.
Last month, Addex announced an update from the phase IIa feasibility study evaluating dipraglurant in patients with blepharospasm, a neurologic disorder causing abnormal contraction of the eyelid muscles.
The study was found to be inconclusive and did not meet all of its objectives.
Addex has no approved product in its portfolio at the moment. Therefore, the successful development of its pipeline candidates remains a key focus for the company.
Addex is developing ADX71149 (mGlu2 positive allosteric modulator or PAM) in collaboration with Janssen Pharmaceuticals, a wholly owned subsidiary of Johnson & Johnson (JNJ - Free Report) .
J&J’s Janssen is leading the phase II study of ADX71149 for treating patients with epilepsy. Janssen is expected to report data from this study in the fourth quarter of 2022.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Precision BioSciences’ loss per share estimateshave narrowed 21.7% for 2022 and 31.4% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Addex (ADXN) Terminates Parkinson's-Related Dyskinesia Study
Shares of Addex Therapeutics Ltd (ADXN - Free Report) tanked on Friday after the company announced that it has terminated the phase IIb/III study evaluating its pipeline candidate, dipraglurant, as a potential treatment for dyskinesia associated with Parkinson’s disease (PD-LID).
The company decided to stop the study owing to the slow recruitment of patients due to COVID-19-related patient concerns over participation in studies. The decision was also taken due to staffing shortages and patient turnover at study sites.
However, the company has stressed that the study termination was not due to dipraglurant.
Shares of Addex have plunged 46.8% so far this year compared with the industry’s decrease of 27.3%.
Image Source: Zacks Investment Research
As a result of the termination of the dipraglurant program for PD-LID, the company subsequently decided to suspend its financial guidance. Addex remains focused on advancing its preclinical candidates into clinical development and entering strategic collaborations for pipeline development.
Last month, Addex announced an update from the phase IIa feasibility study evaluating dipraglurant in patients with blepharospasm, a neurologic disorder causing abnormal contraction of the eyelid muscles.
The study was found to be inconclusive and did not meet all of its objectives.
Addex has no approved product in its portfolio at the moment. Therefore, the successful development of its pipeline candidates remains a key focus for the company.
Addex is developing ADX71149 (mGlu2 positive allosteric modulator or PAM) in collaboration with Janssen Pharmaceuticals, a wholly owned subsidiary of Johnson & Johnson (JNJ - Free Report) .
J&J’s Janssen is leading the phase II study of ADX71149 for treating patients with epilepsy. Janssen is expected to report data from this study in the fourth quarter of 2022.
Zacks Rank & Stocks to Consider
Addex currently carries a Zacks Rank #4 (Sell). Better-ranked stocks in the biotech sector are Leap Therapeutics, Inc. (LPTX - Free Report) and Precision BioSciences, Inc. (DTIL - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Precision BioSciences’ loss per share estimateshave narrowed 21.7% for 2022 and 31.4% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.